Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MAIA
stocks logo

MAIA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.130
-34.06%
--
--
-0.180
+12.5%
--
--
-0.220
+31.03%
Estimates Revision
Stock Price
Go Down
down Image
-22.08%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Maia Biotechnology Inc (MAIA.A) is -1.74, compared to its 5-year average forward P/E of -1.49. For a more detailed relative valuation and DCF analysis to assess Maia Biotechnology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.49
Current PE
-1.74
Overvalued PE
-0.56
Undervalued PE
-2.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.77
Undervalued EV/EBITDA
-1.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.42
Current PS
0.00
Overvalued PS
4.69
Undervalued PS
-1.85
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 673.44% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 673.44% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MAIA News & Events

Events Timeline

(ET)
2025-11-21
09:06:34
MAIA Biotechnology emphasizes progress in ateganosine clinical trials
select
2025-10-23 (ET)
2025-10-23
08:37:01
MAIA Biotechnology reports 30-month survival rates for patients in Phase 2 trial of NSCLC
select
2025-10-13 (ET)
2025-10-13
16:29:37
MAIA Biotechnology to conduct private placement of 603,769 shares at a price of $1.22 each
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-01Globenewswire
MAIA Biotechnology Executives Purchase 182,445 Shares, Signaling Confidence
  • Executive Purchases: MAIA Biotechnology's CEO and board members acquired approximately 182,445 shares of common stock at an average price of $1.06 between November 21 and 28, 2025, reflecting their confidence in the company's future prospects.
  • CEO Stock Acquisition: CEO Vlad Vitoc purchased 94,300 shares during the same period at an average price of $1.08, indicating strong belief in the potential of ateganosine for treating non-small cell lung cancer.
  • Clinical Trial Results: The Phase 2 THIO-101 trial has shown a 38% response rate and an overall survival of 17.8 months for ateganosine, supporting the company's strategic focus in the oncology sector.
  • Board Confidence: Board members Cristian Luput and Stan V. Smith purchased a combined total of 88,145 shares at an average price of $1.04, emphasizing their belief in the long-term value of MAIA's cancer therapy platform.
[object Object]
Preview
9.0
11-10Newsfilter
Diamond Equity Research Publishes Update on MAIA Biotechnology, Inc. (NYSE: MAIA)

  • MAIA Biotechnology's Phase 2 Trial Results: The company reported a significant milestone in its Phase 2 THIO-101 trial for advanced non-small cell lung cancer (NSCLC), showcasing a patient achieving 30 months of survival, which is exceptional for this high-risk group.

  • NIH Grant for Trial Expansion: MAIA has been awarded a $2.3 million grant from the NIH to expand its THIO-101 trial in the U.S., highlighting the drug's potential effectiveness and the growing institutional support for its development.

  • Financial Performance Overview: In Q3 2025, MAIA reported a net loss of $8.90 million, with increased operating expenses primarily due to R&D efforts, while also noting a cash position of $10.89 million at quarter-end.

  • Valuation and Future Prospects: The company's valuation has been revised to $10.27 per share, contingent on successful clinical execution, with ongoing positive trial results serving as a catalyst for potential future growth and registration of THIO-101.

[object Object]
Preview
9.0
10-27Newsfilter
MAIA Biotechnology Showcases Ongoing Trial Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Treatments

  • Clinical Trial Enrollment: MAIA Biotechnology has enrolled the first five patients in the expansion phase of its THIO-101 Phase 2 clinical trial in Taiwan and Turkey, focusing on advanced non-small cell lung cancer (NSCLC) resistant to prior treatments.

  • Conference Presentation: At the 2025 AACR-NCI-EORTC Conference, MAIA's Sr. Medical Director presented updates on the THIO-101 trial, highlighting a favorable safety profile and ongoing enrollment efforts across multiple countries.

  • Potential Impact of Ateganosine: The investigational drug ateganosine is being evaluated for its ability to enhance immune responses in NSCLC patients, particularly in regions like Turkey where lung cancer is a significant public health issue.

  • Research Background: The high prevalence of smoking and air pollution in Turkey contributes to NSCLC cases, with ateganosine potentially offering a breakthrough treatment option for patients who have not responded to existing therapies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Maia Biotechnology Inc (MAIA) stock price today?

The current price of MAIA is 1.2 USD — it has increased 7.14 % in the last trading day.

arrow icon

What is Maia Biotechnology Inc (MAIA)'s business?

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

arrow icon

What is the price predicton of MAIA Stock?

Wall Street analysts forecast MAIA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MAIA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Maia Biotechnology Inc (MAIA)'s revenue for the last quarter?

Maia Biotechnology Inc revenue for the last quarter amounts to -9.36M USD, increased 124.31 % YoY.

arrow icon

What is Maia Biotechnology Inc (MAIA)'s earnings per share (EPS) for the last quarter?

Maia Biotechnology Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Maia Biotechnology Inc (MAIA)'s fundamentals?

The market is revising No Change the revenue expectations for MAIA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -22.08%.
arrow icon

How many employees does Maia Biotechnology Inc (MAIA). have?

Maia Biotechnology Inc (MAIA) has 13 emplpoyees as of December 05 2025.

arrow icon

What is Maia Biotechnology Inc (MAIA) market cap?

Today MAIA has the market capitalization of 44.44M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free